Abstract:NAC1 is a nuclear factor belonging to the BTB gene family. The BTB domain of NAC1 is responsible for its homodimerization and interaction with other proteins to form a complex that plays an important role in maintaining the pluripotency of ES cells and in the development of chemoresistance in ovarian cancer cells. Elucidating the molecular mechanisms underlying how NAC1 contributes to drug resistance is fundamental to improve clinical outcome in recurrent postchemotherapy ovarian cancer patients. The purpose of this study was to determine whether autophagy, a conserved response to several types of stresses including therapeutic stress, was involved in NAC1-mediated resistance to cisplatin, a commonly used chemotherapeutic drug in the treatment of ovarian cancer. We found that treatment with cisplatin caused a robust activation of autophagy in NAC1-expressing ovarian cancer cell lines including A2780, OVCAR3, and SKOV3, based on the alteration of LC3-II and p62 by Western blot analysis, and the presence of GFP-LC3 puncta by microscopic observation. We further demonstrated that knockdown of NAC1 expression by RNA interference or inactivation of NAC1 by inducing the expression of NAC1 deletion mutant that contains only the BTB domain significantly inhibited the cisplatin-induced autophagy, resulting in increased cisplatin cytotoxicity as measured by MTT viability assay. Moreover, we observed that inhibition of autophagy and sensitization to cisplatin by NAC1 knockdown or inactivation were accompanied by induction of apoptosis, as evidenced by increases in Annexing V staining and in the levels of proapoptotic proteins caspase-3 and PARP. To confirm that the sensitizing effect of NAC1 inhibition on the cytotoxicity of cisplatin was mediated through suppression of autophagy, we assessed the effects of autophagy inhibitors, 3-MA and chloroquine, on the cytotoxicity of cisplatin. Treatment of cancer cells with 3-MA and chloroquine also enhanced the sensitivity of SKOV3, A2780, and OVCAR3 cells to cisplatin, indicating that suppression of autophagic response indeed renders the NAC1-expressing ovarian cancer cells more sensitive to cisplatin. The regulation of autophagy by NAC1 appeared to be mediated via HMGB1 (high-mobility group box 1), as NAC1 could regulate the expression, translocation and release of HMGB1, which is known to activate autophagy by disrupting the interaction between beclin 1 and bcl-2. The results of our study not only revealed a new mechanism governing cisplatin sensitivity but also identified NAC1 as a novel regulator of autophagy. Thus, the NAC1-mediated autophagy may be exploited as a new target for enhancing the efficacy of cisplatin against ovarian cancer or other types of malignancies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the Second AACR International Conference on Frontiers in Basic Cancer Research; 2011 Sep 14-18; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2011;71(18 Suppl):Abstract nr C63.

Nucleosome Assembly Protein 1-Like 3 Enhances Cisplatin Resistance of Ovarian Cancer Cell by Activating Transforming Growth Factor-Beta Pathway.

The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer

Nucleus accumbens-1/GADD45GIP1 axis mediates cisplatin resistance through cellular senescence in ovarian cancer

Protein Tyrosine Phosphatase PTPN3 Promotes Drug Resistance and Stem Cell-Like Characteristics in Ovarian Cancer

NAC1 Modulates Sensitivity of Ovarian Cancer Cells to Cisplatin by Altering the HMGB1-mediated Autophagic Response

Abstract C63: Identification of NAC1 as a novel regulator of autophagy: Its implication in cisplatin resistance

METTL3‐mediated m6A modification of lnc RNA RHPN1‐AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway

Npgc1α PROMOTES CISPLATIN RESISTANCE IN HUMAN OVARIAN CARCINOMA CELLS THROUGH UPREGULATION OF MITOCHONDRIA BIOGENESIS

Cisplatin-induced CCL5 Secretion from CAFs Promotes Cisplatin-Resistance in Ovarian Cancer Via Regulation of the STAT3 and PI3K/Akt Signaling Pathways.

Cul4 E3 Ubiquitin Ligase Regulates Ovarian Cancer Drug Resistance by Targeting the Antiapoptotic Protein BIRC3.

Elevating H3K27me3 Level Sensitizes Colorectal Cancer to Oxaliplatin.

Phospho-Delta Np63 Alpha/Srebf1 Protein Interactions Bridging Cell Metabolism And Cisplatin Chemoresistance

SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG

Nuclear Orphan Receptor NR2F6 Confers Cisplatin Resistance in Epithelial Ovarian Cancer Cells by Activating the Notch3 Signaling Pathway.

Chemokine CX3CL1/CX3CR1 biological axis promote ovarian cancer cell apotosis induced by platinum drug

NAP1L1 is a Prognostic Biomarker and Contribute to Doxorubicin Chemotherapy Resistance in Human Hepatocellular Carcinoma

PGC1α regulates mitochondrial oxidative phosphorylation involved in cisplatin resistance in ovarian cancer cells via nucleo-mitochondrial transcriptional feedback

lncRNA MIAT/HMGB1 Axis Is Involved in Cisplatin Resistance via Regulating IL6-Mediated Activation of the JAK2/STAT3 Pathway in Nasopharyngeal Carcinoma

CSTF3 contributes to platinum resistance in ovarian cancer through alternative polyadenylation of lncRNA NEAT1 and generating the short isoform NEAT1_1

FGFR3 Phosphorylates EGFR to Promote Cisplatin-Resistance in Ovarian Cancer.

VPS33B Interacts with NESG1 to Suppress Cell Growth and Cisplatin Chemoresistance in Ovarian Cancer